Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1037 results
February 2015
-
Media ReleasePositive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degenerationPhase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Novartis Board of DirectorsShareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
-
Media ReleaseNovartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinibIf approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
-
Media ReleaseNovartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myelomaFarydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority reviewDecision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
-
Media ReleaseAlcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch reliefUS Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
January 2015
-
Media ReleaseNovartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia veraJakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
-
Media ReleaseNovartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businessesNet sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
-
Media ReleaseNovartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the USWith today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
-
Media ReleaseNovartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia veraPolycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
-
Media ReleaseNovartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patientsOffering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
Pagination
- ‹ Previous page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- › Next page